

HOTEL ACCOMMODATION FORM

Please complete and return to: **CQ Travel srl** - Via Pagliano 3 - 20149 Milano
e-mail: congress@cq-travel.com - Fax: +39 0243911650

TO BE FILLED OUT IN CAPITAL LETTERS

HOTEL ACCOMMODATION FORM

First Name _____	Last Name _____	
Address _____		
Post code _____	City _____	Country _____
Telephone _____		Fax _____
E-mail _____		Codice Fiscale (only for Italian participants) _____

LIST OF HOTELS

Prices are for day for bed and breakfast in Euros and also include: daily bus transfer from hotels to the congress venue, taxes and handling fee. Please indicate the required accommodation.

CHOICE	*	<input type="checkbox"/> DOUBLE ROOM	<input type="checkbox"/> DOUBLE SINGLE USE
<input type="checkbox"/> Quark Hotel (conference venue) Via Lampedusa 11/a	4	€ 195	€ 165
<input type="checkbox"/> Cusani Hotel (city center) Largo Cairoli	4	€ 300	€ 225
<input type="checkbox"/> Jolly President Hotel (city center) Largo Augusto	4	€ 270	€ 230
<input type="checkbox"/> Grand Visconti Palace Hotel (south Milan) Lodi square	4	€ 240	€ 210
<input type="checkbox"/> Major Hotel (south Milan) Lodi Square	4	€ 170	€ 140
<input type="checkbox"/> Sporting Hotel (south Milan) Opera Sporting Mirasole	4	€ 150	€ 105
<input type="checkbox"/> Dei Fiori Hotel (south Milan) Via Renzo e Lucia	3	€ 140	€ 120

Arrival date _____	Departure date _____
Total number of nights _____	Signature _____

For confirmation, please enclose the payment for the whole period. The rooms will be allocated on a first come first served basis.

Deadline for hotel reservation: 14 April 2007. After this date rooms and special rates will not be guaranteed and reservations will only be accepted on the basis of availability.

TERMS OF PAYMENT

Full payment of the total is requested on booking.

_____ per night _____ (numbers of nights) = Total _____

Bank transfer to the order of CQ TRAVEL s.r.l.
Banca Intesa: Iban IT27N0306909568068142300160 - swift code BCITITMM327
Abi 03069 - Cab 09568 - Account n. 68142300160

CREDIT CARD Visa Mastercard American Express
N° _____ Exp. date _____

Card holder's name in CAPITAL LETTERS _____

Card holder's signature _____

ABSTRACT DEADLINE APRIL 14 2007

You may submit your abstract:
• By e-mail to mbcc@ieo.it

• by floppy disk to the Scientific Secretariat,
European Institute of Oncology
Via Ripamonti, 435, 20141 Milan, Italy

INSTRUCTIONS FOR ABSTRACT SUBMISSION

Participants with new data relevant to the subjects of the conference may submit one abstract to be considered for poster presentation. Only papers whose abstracts have been reviewed and approved by the Scientific Committee will be presented.

Abstracts must be written in English and the text should not exceed 2000 characters (title included).

The title should appear in capital letters.

For each author, type surname first followed by

given name and initials (presenting author in capital letters).

List affiliations after the authors' list.

The full address with telephone, fax number, and e-mail of the corresponding author must be provided. This author will receive all the subsequent communication concerning this abstract.

Please indicate your approval for publication in case the abstracts will be issued in a journal.

Please note:

Only abstracts submitted by registered participants will be accepted. Please do not forget to mark on the registration form that you have submitted an abstract.

It is the responsibility of the presenting author to ascertain whether all authors are aware of the content of the abstract before submission.

GENERAL INFORMATION

CONFERENCE VENUE

Quark Hotel Via Lampedusa, 11/A - 20141 Milano
Tel: 02 84431 - Fax: 02 8464190 www.atahotels.it
The Quark Hotel is a 15 minutes drive from the city centre.

SCIENTIFIC SECRETARIAT

European Institute of Oncology
Via Ripamonti, 435 - 20141 Milano
Tel: +39-02 57489227
Fax: +39-02 57489210 - E-mail: mbcc@ieo.it

ORGANISING SECRETARIAT

CQ Travel srl - Via Pagliano 3 - 20149 Milano
Tel. +39-02-480495.1 - Fax. +39-02-43911650
e-mail: congress@cq-travel.com

CONFIRMATION OF REGISTRATION

Registration will only be confirmed upon receipt of the registration fee.

A combined confirmation of registration or acknowledgment of payment will be sent by mail, fax or e-mail, as preferred, upon receipt of the payment.

CANCELLATION OF REGISTRATION

In case of cancellation without replacement, the fee less handling charges of 60 EURO will be refunded, provided a written request is received by CQ Travel before 2nd June 2007.

No refund can be made if notice of cancellation is received after this date. Any refund will be made after the conference.

CME ACCREDITATION

The European Institute of Oncology will apply for CME credits to the Accreditation Council of Oncology in Europe and to the Italian Ministry of Health.

Each participant will receive a certificate of attendance stating the relevant number of credits obtained during the conference.

American doctors attending the conference can report this to the AMA and receive AMA PRA Cat. 1 credit.

The CME certificates can be granted only to the participants who have attended the entire conference. The CME certificates will be distributed only at the end of the meeting.




9th Milan Breast Cancer Conference

JUNE 20-22
2007

Innovation in Care and Research

CHAIR
U. VERONESI
A. GOLDHIRSCH



Dear Colleague,

It is a pleasure for us to welcome you to the 9th Milan Breast Cancer Conference - a conference of innovations in patient care. It intends to perpetuate the environment for creative discussion, involving participants and faculty members, which is the motivation for the 2007 edition. The conference will continue to be based upon new information, consolidated knowledge, and interaction on controversial issues regarding diagnosis, treatment strategies and disease prevention. The ninth assembly of this conference will provide, we hope, a friendly, stimulating forum for the presentation of innovation, ongoing and future research on breast cancer.

This year's conference will focus upon three important features. The first relates to tailored approaches to patients with the disease. Breast cancer is a heterogeneous disease, which presents in very different ways and in patients who have very different biological, social and human characteristics. The opportunities for a tailored surgery and radiation therapy are greater than ever in the past. Pathological and biological assessment, genetics and molecular evaluation are integrated into therapeutic decision making strategies and trials are designed to raise the yield of profiling for treatment choice. The prejudice of a "one size fit all" is being more than ever challenged by focusing on how diversity should be used to improve treatment outcome. The availability of targeted systemic treatments, like an increased number of endocrine agents, monoclonal antibodies, and several agents which interact with strategically important cellular components, indicates a significant progress in care and an incentive for further developments based upon molecular medicine technology. Applying novel knowledge to strategies of prevention of breast cancer are therefore the main feature of the European Institute of Oncology Award Lecture at the opening of the conference. As in the past, refinements of multidisciplinary approaches include surgery, intra and postoperative radiation therapy to obtain the best local disease control and minimize the side effects of proper treatment. Part of such programs include also preoperative systemic therapies aimed at allowing a more efficient control of local disease and at obtaining information on tumor regression with specific therapies to improve knowledge on tailoring of treatment. The 2007 Milan Breast Cancer Conference continues also to provide knowledge on special problems of specific treatments and the associated costs. Special attention is given to cardiac toxicity of agents like trastuzumab, and to side effects of novel endocrine agents, while their use is being extended to larger populations.

A second aspect relates to the changing features of care and the need to prioritize prevention, diagnostic and therapeutic approaches. These aspects of prioritization are particularly precious because of increased weight of regulations in applying medicine in general and cancer medicine in particular.

A third aspect relates to discussion of the latest features of the St. Gallen Expert Consensus 2007. Newer aspects of how to approach controversies of interpretation of evidence from clinical trials will be therefore discussed focusing upon features which need to be refined again.

Milan, a capital of breast cancer research, continues to house a tradition of innovation, care and research for the field of breast cancer. Reports on new surgical approaches, improved radiation treatments, and advances in medical therapies are a guarantee, as in the past, for an exciting and fruitful conference.

Welcome! We hope you have an enjoyable and inspiring conference.

Umberto Veronesi and Aron Goldhirsch

CONFERENCE CO-ORDINATORS

S. Cinieri - M. Colleoni - S. Zurrada



www.breastmilan.com

SECOND ANNOUNCEMENT

INTERNATIONAL INVITED FACULTY

Bellomi Massimo	European Institute of Oncology, University of Milan, IT
Bertolini Francesco	European Institute of Oncology, Milan, IT
Bonanni Bernardo	European Institute of Oncology, Milan, IT
Bonizzi Giuseppina	European Institute of Oncology, Milan, IT
Burstein Harold	Dana Farber Cancer Institute, Boston, USA
Clarke Michael F.	Stanford University School of Medicine, Stanford, USA
Colleoni Marco	European Institute of Oncology, Milan, IT
Costa Alberto	Fondazione Salvatore Maugeri, Pavia, IT
Curigliano Giuseppe	European Institute of Oncology, Milan, IT
Decensi Andrea	Ospedale Galliera, Genoa, IT
Dellapasqua Silvia	European Institute of Oncology, Milan, IT
Di Leo Angelo	Ospedale Misericordia e Dolce, Prato, IT
Ford Leslie	National Cancer Institute, Bethesda, USA
Fuqua Suzanne A.W.	Baylor College of Medicine, Houston, USA
Galimberti Viviana	European Institute of Oncology, Milan, IT
Gentilini Oreste	European Institute of Oncology, Milan, IT
Ginestier Christophe	Comprehensive Cancer Center, University of Michigan, Ann Arbor, USA
Glück Stefan	Braman Family Breast Cancer Institute, University of Miami, Miami, USA
Goldhirsch Aron	European Institute of Oncology, Milan, IT
Goss Paul	Massachussetts General Hospital, Boston, USA
Harris Adrian	Churchill Hospital, Oxford, UK
Heywang-Köbrunner Sylvia	Technical University of Munich - SHHK, Munich, DE
Ingle James	Mayo Clinic, Rochester, USA
Intra Mattia	European Institute of Oncology, Milan, IT
Ivaldi Giovanni	European Institute of Oncology, Milan, IT
Leonardi Maria Cristina	European Institute of Oncology, Milan, IT
Mantovani Alberto	Istituto Clinico Humanitas, Rozzano, IT
Munzone Elisabetta	European Institute of Oncology, Milan, IT
Olmi Patrizia	Istituto Nazionale dei Tumori, Milan, IT
Orecchia Roberto	European Institute of Oncology, University of Milan, IT
Orlando Laura	European Institute of Oncology, Milan, IT
Paganelli Giovanni	European Institute of Oncology, Milan, IT
Pece Salvatore	European Institute of Oncology, Milan, IT
Petit Jean Yves	European Institute of Oncology, Milan, IT
Pruneri Giancarlo	European Institute of Oncology, Milan, IT
Rizzatto Giorgio	Ospedale Civile di Gorizia, Gorizia, IT
Smith Gilbert H.	National Cancer Institute, Bethesda, USA
Surbone Antonella	European School of Oncology, Milan, IT
Suter Thomas	Klinik und Poliklinik für Kardiologie, Bern, CH
Taghian Alphonse	Massachussetts General Hospital, Boston, USA
Tavitian Bertrand	Service Hospitalier Frédérique Joliot, CEA Orsay, FR
Torrisi Rosalba	European Institute of Oncology, Milan, IT
Trentin Chiara	European Institute of Oncology, Milan, IT
Veronesi Paolo	European Institute of Oncology, Milan, IT
Veronesi Umberto	European Institute of Oncology, Milan, IT
Viale Giuseppe	European Institute of Oncology, University of Milan, IT
Villadsen René	The Panum Institute, Institute for Cellular and Molecular Medicine, Copenhagen, DK
Vogel Victor G.	Magee - Women's Hospital, University of Pittsburgh, Pittsburg, USA
Wei Wei-Zen	Karmanos Cancer Institute, Wayne State University, Detroit, USA
Wolff Antonio C.	The Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Zurrida Stefano	Istituto Nazionale dei Tumori, Milan, IT

WEDNESDAY 20th JUNE

- 17.00 **Welcome**
- 17.05 **EIO Award:** *Leslie Ford*
- Lecture**
Prevention of Breast Cancer:
historical milestones and future galaxies
- 17.45 **Satellite Symposia**
- 19.30 Cocktail

THURSDAY 21st JUNE

- 08.15 **Welcome and Opening**
- THE MULTIFACETED BREAST CANCER: MOVING TOWARDS MOLECULAR PHENOTYPING**
Chair: Giuseppe Viale
Rapporteur: Giancarlo Pruneri
- 08.30 Evolution of pathological definition of breast cancer
Suzanne A.W. Fuqua
- 08.45 The special case of HER2-positive breast cancer
Giuseppe Viale
- 09.00 Specific approach to basal-like breast cancer
Angelo Di Leo
- 09.15 Therapeutic implications for endocrine responsive cancers (luminal types)
René Villadsen
- 09.30 Discussion
- 09.40 **SPOTLIGHT:**
Prevention of breast cancer: new insight
Andrea Decensi
- TUMOR STEM CELLS: RETHINKING BREAST CANCER**
Chair: Salvatore Pece
Rapporteur: Giuseppina Bonizzi
- 10.00 Stem cells and their particular features
Ginestier Christophe
- 10.20 Reality or science fiction: targeting the stem cell
Gilbert H. Smith
- 10.35 Coffee Break
- 11.00 Stem cell and premalignant disorders
Michael F. Clarke
- 11.15 Stem cell and breast carcinogenesis
Salvatore Pece
- 11.30 Discussion
- 11.45 **LIVE SURGERY WITH COMMENTARY**
Speaker: Mattia Intra
- ROLL
- Nipple sparing mastectomy

- 12.45 Lunch
- INFLAMMATION & IMMUNITY**
Chair: Alberto Mantovani
Rapporteur: Elisabetta Munzone
- 13.45 Hypoxia, angiogenesis and progression of breast cancer
Adrian L. Harris
- 14.00 Metronomic treatments, suppression of inflammation, and regression of cancer
Francesco Bertolini
- 14.15 Immunity to breast cancer antigen vs. thyroid antigen
Wei-Zen Wei
- 14.30 Active immunisation and treatment of breast cancer
Giuseppe Curigliano
- 14.45 Discussion
- 15.00 **SPOTLIGHT:**
St. Gallen 2007: "First aim at the target..."
Aron Goldhirsch
- CHEMOPREVENTION**
Chair: Andrea Decensi
Rapporteur: Bernardo Bonanni
- 15.20 Other new indications for raloxifene?
Leslie Ford
- 15.35 Should we change trials with aromatase inhibitors for prevention?
Victor G. Vogel
- 15.50 Retinoids as a preventive drug in young women
Bernardo Bonanni
- 16.05 Discussion
- 16.20 Coffee Break
- IMAGING OF BREAST CANCER: CURRENT AND FUTURE METHODS**
Chair: Massimo Bellomi
Rapporteur: Chiara Trentin
- 16.45 The innovations in ultrasound
Giorgio Rizzatto
- 17.00 The role of magnetic resonance
Sylvia Heywang Köbrunner
- 17.15 Looking for local recurrences and distant metastases with PET
Giovanni Paganelli
- 17.30 Molecular imaging of the breast
Bertrand Tavitian
- 17.45 Discussion
- 18.15 **Satellite Symposia**

FRIDAY 22nd JUNE

- FUTURE OF SURGERY AND CLASSIFICATION**
Chair: Stefano Zurrida
Rapporteur: Oreste Gentilini
- 08.15 Extended indications for sentinel node biopsy procedures and internal mammary node assessment
Paolo Veronesi
- 08.35 What is the best treatment for lobular invasive carcinoma?
Viviana Galimberti
- 08.50 Preservation of breast image: a new avenue in breast surgery
Jean Yves Petit
- 09.05 Future evolution of the TNM: concrete approaches
Umberto Veronesi
- 09.20 Discussion
- RADIATION THERAPY: WHEN, HOW, FOR WHOM**
Chair: Patrizia Olmi
Rapporteur: Maria Cristina Leonardi
- 09.35 The rationale for Partial Breast Irradiation: the Intraoperative Electron beams radiotherapy (ELIOT)
Roberto Orecchia
- 09.50 ELIOT plus accelerated external radiotherapy
Giovanni Ivaldi
- 10.05 The use of proton beams in the treatment of breast cancer
Alphonse Taghian
- 10.20 Discussion
- 10.30 Coffee Break
- 11.00 **SPOTLIGHT:**
Assessing margins of excision: what is it all about?
Umberto Veronesi
- The Milan Breast Cancer Observatory: Innovation and care in the next 12 months**
Sponsored by the European School of Oncology
- Participants:*
Monica Castiglione-Gertsch
Leslie Ford
Viviana Galimberti
Aron Goldhirsch
Paul Goss
Adrian Harris
Chair: Alberto Costa
- 12.20 Lunch



- 13.30 **SPOTLIGHT:**
The breast cancer survivors
Antonella Surbone
- 13.40 **SPOTLIGHT:**
Cardiac toxicity in breast cancer survival
Thomas Suter
- ENDOCRINE ADJUVANT THERAPIES: NEW STANDARDS AND NEW AVENUES**
Chair: Paul Goss
Rapporteur: Silvia Dellapasqua
- 14.00 The evolving chapter of adjuvant aromatase inhibitors
Paul Goss
- 14.15 Ovarian function ablation and being a woman: how to reconcile?
Antonio C. Wolff
- 14.30 What would I want to know more about duration of adjuvant endocrine therapies
James Ingle
- 14.45 Discussion
- CHEMOTHERAPY, HER2/NEU AND OTHER TARGETED THERAPIES**
Chair: Antonella Surbone
Rapporteur: Rosalba Torrisi
- 15.00 Adjuvant trastuzumab and beyond
Stefan Glück
- 15.15 New information on HER2/neu and new targeted therapies
Rosalba Torrisi
- 15.30 Taxing the taxanes in adjuvant setting
Angelo Di Leo
- 15.45 Discussion
- 16.00 Coffee Break
- SYSTEMIC THERAPIES: SPECIAL ISSUES**
Chair: Antonio C. Wolff
Rapporteur: Laura Orlando
- 16.30 Tailored preoperative systemic therapy: new aspects for targeting treatments
Marco Colleoni
- 16.45 The axillary lymph node metastases with no primary breast cancer: what to do?
Harold Burstein
- 17.00 Discussion and Closing remarks

REGISTRATION FORM

REGISTRATION FORM or register online at www.breastmilan.com
please complete and return this form to
CQ TRAVEL s.r.l.
via Pagliano,3 - 20149 Milan Italy - tel: + 39-02 4804951 - e-mail: congress@cq-travel.com
Please print or type and make a copy for your own record. This form may be sent by post or fax to: +39-02 43911650

TO BE FILLED OUT IN CAPITAL LETTERS

REGISTRATION FORM

First Name	Last Name		
Company/Institute			
Department			
Specialty	Surgeon <input type="checkbox"/>	Radiotherapist <input type="checkbox"/>	Medical Oncologist <input type="checkbox"/>
Address			
Post code	City	Country	
Telephone		Fax	
E-mail			
Only for Italian participants: Partita IVA or codice fiscale			

REGISTRATION FEE

Early rate	payment received BEFORE MARCH 30, 2007	550 EURO <input type="checkbox"/>
Late rate	payment received FROM MARCH 31 TO MAY 25, 2007	650 EURO <input type="checkbox"/>
On site	payment received FROM MAY 26, 2007	850 EURO <input type="checkbox"/>

9th MBCC + Breast Cancer Oncologic and Rec. Surgery **1000 EURO 1200 EURO (on site)**

EUSOMA, EORTC, EUROPA DONNA and SIS members and ex-allievi SIS are entitled to 30% discount only for the 9th MBCC

EUSOMA member EUROPA DONNA member
 EORTC member SIS member ex allievi SIS

The registration fee covers admission to the congress and exhibition, a copy of the programme, coffee and lunch throughout the congress and the official welcome cocktail.

ACCOMPANYING PERSON Name

Accompanying persons will be admitted free of charge to the welcome cocktail.

ABSTRACT: I have submitted an abstract (See instructions in the programme)

I authorize the European Institute of Oncology to use my personal data for purposes relating to the School's activities.

Signature

PAYMENT BY

CHEQUE PAYABLE TO **CQ TRAVEL s.r.l.** via Pagliano,3 - 20149 Milan Italy

BANK TRANSFER to the order of CQ Travel srl
Banca Sella: IBAN IT38S0326801600052866945211 - swift code: SELBIT2B
Abi 03268 - Cab 01600 - account nbr 052866945211

CREDIT CARDS American Express Visa (Carta Si-Master Card-Eurocard)

N° Exp. date

Card holder's name in CAPITAL LETTERS

Card holder's signature